Bioclinic of Thessaloniki

Thessaloniki 54622

0 studies enrolling now · 6 studies all time

What they study most

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, KRAS p, G12c Mutated /Advanced Metastatic NSCLC, Locally Advanced or Unresectable Metastatic Breast Cancer, Melanoma, Stage IV Breast Cancer

Studies at this site

• Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). — Completed
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Completed
• Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). — Completed
• Registry Study for Talimogene Laherparepvec — Completed